TABLE 5.

Consensus statements on screening and monitoring requirements for PsA therapies

Recommendations
Recommended laboratory tests prior to initiation of a biologic treatment include: 9 , 13 o Complete blood count: hemoglobin, hematocrit, white blood cell count, white blood cell differentiation, and platelet count o Comprehensive liver function tests: direct bilirubin, total bilirubin, ALP, ALT, and GGT o Renal function test Other important tests include ESR, CRP, and serum creatinine.
Screening for HIV, HBV, HCV, and tuberculosis (QuantiFERON preferable) should be strongly considered, in accordance with local guidelines and standards of medical practice before initiation of therapies that may potentially alter normal immune response. 9
Inclusion of varicella‐zoster antibody (IgG) test, especially in patients taking JAKi, for baseline tests, should be considered. 142
Chest X‐ray as a baseline monitoring test for all drugs should be strongly considered.
A general screening questionnaire for malignancy should be considered on a case‐by‐case basis.
Given the increased prevalence and incidence of CVD and diabetes among patients with PsA, regular screening is recommended (eg Framingham risk score or ASCVD for CVD risk assessment). 9
Screening for depression and anxiety among patients with PsA should also be considered. 9
Given the association of ophthalmic disease with spondylarthritis and an increased risk of IBD among patients with PsA, consideration of screening for eye disease and Gastrointestinal disease is recommended as a part of the review of systems, as well as consideration of appropriate referral, as applicable. 9
Monitoring tests should be conducted every 1–3 mo during treatment and based on clinical judgment.

Abbreviations: ALP, alkaline phosphatase; ALT, alanine transaminase; ASCVD, atherosclerotic cardiovascular disease; CRP, C‐reactive protein; CVD, cardiovascular disease; ESR, erythrocyte sedimentation rate; GGT, G‐glutamyl transferase; HBV, hepatitis B virus; HCV, hepatitis C virus; HIV, human immunodeficiency virus; IBD, inflammatory bowel disease; IgG, immunoglobulin G; JAKi, Janus kinase inhibitor; PsA, psoriatic arthritis.